Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

The next step in cardiovascular protection.

Cannon CP.

Atheroscler Suppl. 2003 Dec;4(5):3-9. Review.

PMID:
14980229
2.
5.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
6.

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2008 Feb 19;51(7):724-30. doi: 10.1016/j.jacc.2007.10.038.

7.

Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.

Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E.

Am J Cardiol. 2002 Apr 1;89(7):860-1. No abstract available.

PMID:
11909576
8.

Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.

Ray KK, Cannon CP.

Curr Opin Lipidol. 2004 Dec;15(6):637-43. Review.

PMID:
15529022
9.

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.

Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2005 Oct 18;46(8):1411-6. Erratum in: J Am Coll Cardiol. 2006 Jan 17;47(2):472.

11.

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.

Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10.

12.

Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?

Ray KK, Cannon CP.

Am J Cardiol. 2005 Sep 5;96(5A):54F-60F. Review.

PMID:
16126024
13.

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A.

Eur Heart J. 2005 May;26(9):890-6.

14.

Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?

Ray KK, Cannon CP, Ganz P.

Am J Cardiol. 2006 Dec 4;98(11A):18P-25P. Review.

PMID:
17126675
16.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-RubiĆ³ P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
17.

Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).

Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D.

Circulation. 2007 Feb 13;115(6):700-7.

18.

Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.

Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A; Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study..

J Am Coll Cardiol. 2001 Jul;38(1):56-63.

20.

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators..

Am J Cardiol. 2007 Sep 1;100(5):747-52.

PMID:
17719314
Items per page

Supplemental Content

Support Center